Evidence map›Paper›PMID 42732027›Full record

ArticleEuropean radiology2026

Comparison of pre-treatment

Yutang Yao, Musi Zhang, Cheng Luo, Meng Zhao, Ying Kou, Hao Lu, Xiao Jiang, Xiaoai Wu, Zhuzhong Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yutang Yao *Department of Nuclear Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Musi Zhang *Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Cheng Luo *Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Meng ZhaoDepartment of Nuclear Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Ying KouDepartment of Nuclear Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Hao LuDepartment of Nuclear Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Xiao JiangDepartment of Nuclear Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. jiangxiao@scszlyy.org.cn.
Xiaoai WuDepartment of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, China. xiaoai.wu@scu.edu.cn.
Zhuzhong ChengDepartment of Nuclear Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. chengzhuzhong126@126.com.ORCID http://orcid.org/0009-0009-3431-6728

Funding

Isotope and Drug Innovation Fund Program TWSCX-2023-CXJJ-9Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0525900Nuclear Technology R&D Project under the 14th Five-Year Plan of the State Administration of Science, Technology and Industry for National Defense HNK202323(36)02Sichuan Medical and Health Care Promotion Institute Scientific Research Project KY2022SJ0260Sichuan Provincial Clinical Key Specialty Construction Project 2024GHYXP002the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University, China Under Grant ZYGD23016
6 · The paper itself

Abstract

objectiveTo investigate the value of MATERIALS AND

methodsThis prospective study enrolled participants with histologically confirmed HNSCC who underwent both

resultsThirty-four participants(median age, 59 years [range, 32-82 years]; 26 men) were enrolled. In the lesion-based analysis (37 lesions from 34 patients),

conclusionKEY POINTS: Question Whether

Indexed as

ImmunotherapyNeoadjuvant therapyPositron-emission tomography computed tomographyProgrammed cell death-ligand 1Squamous cell carcinoma of head and neck

Identifiers

PMID42732027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.